血管活性物质的分布与肝肾综合征的发病机制  

Distribution of the vascular activated substance and the pathogenesis of the hepatorenal syndrome

作　　者：李晓鸥[1] 朱元东[1] 娄国强[1] 

机构地区：[1]杭州市第六人民医院五病区,310014

出　　处：《国际流行病学传染病学杂志》2006年第4期258-260,287,共4页International Journal of Epidemiology and Infectious Disease

基　　金：杭州市卫生局2001年科技A类计划(01A044)

摘　　要：肝肾综合征(hepatorenalsyndrome,HRS)是严重肝病时发生的一种严重的、功能性的肾功能衰竭,是肝病患者终末期的常见并发征。HRS发病机制目前比较公认的观点是全身有效血容量减少,导致肾脏血流灌注不足,以及血管舒缩物质的异常并导致肾小球动脉过度收缩。文章就炎症因子与HRS的发病机制进行探讨。The hepatorenal syndrome（ HRS） is a severe functional renal failure, which is a common complication in the late phase of hepatic diseases. Presently,the common view to the mechanism of HRS is the decreasing of the body effective blood volume, which results in the lack of renal perfusion, and the abnormality of the vascular activated substance, which results in constricting over the renal globule artery. We consider that the hepatic failure, the abnormal of vascular activated substance and the disorder of whole body blood dynamics are the important factor to HRS. Particularly, the abnormality of the vascular activated substance is a main reason in the all.

关 键 词：肝肾综合征 血管活性物质 肾素 心房肽 一氧化氮 内皮素 血液动力学 

分 类 号：R575[医药卫生—消化系统]